Trontinemab (RG6102) is a human IgG1-kappa antibody selectively targeting Abeta precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimers disease.
CAS Number:
[2568868-35-7]
Target:
Beta Amyloid
* VAT and and shipping costs not included. Errors and price changes excepted
